"Ipsen Acquires ImCheck Therapeutics for Up to EUR 1 Billion to Enhance Oncology Pipeline"

"A&O Shearman is advising Ipsen, a global biopharmaceutical company, on its acquisition of ImCheck Therapeutics, a French biotech firm specializing in immuno-oncology therapies, for a potential total of up to EUR1 billion. The acquisition focuses on ImCheck's clinical-stage program ICT01, a promising treatment for acute myeloid leukemia (AML) that could become a new standard of care. The deal is expected to close by the end of Q1 2026, pending regulatory approvals. Marc Castagnède, a partner at A&O Shearman, highlighted the firm's expertise in supporting complex transactions in the life sciences sector."

A&O Shearman advised Ipsen, a global biopharmaceutical company, on its acquisition of ImCheck Therapeutics, a private French biotechnology company. The transaction involves Ipsen acquiring ImCheck Therapeutics for a total potential consideration of up to EUR 1 billion, focusing on the clinical-stage program ICT01, which targets acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy or targeted treatments. The acquisition is expected to close by the end of Q1 2026, pending customary closing conditions and regulatory approvals. The A&O Shearman team was led by M&A partner Marc Castagnède, with support from M&A senior associate Antoine Messent and associate Fatima Ahamada. Other members of the Paris team included partner Olivier Picquerey and senior associate Antoine Tantaro on employment matters; partners Laëtitia Bénard and Charles Tuffreau, associate Manon Perret, and consultant Marianne Delassaussé on IP matters; senior associate Clémence d’Almeida on antitrust matters; counsel Luc Lamblin and associate Charles-Hugo Lerebour on regulatory and FDI matters; partner Laurie-Anne Ancenys and associate Thomas Feigean on IT and data aspects; and partner Charles del Valle on tax matters. Additionally, support was provided by the A&O Shearman US corporate and antitrust teams.

"Ipsen Acquires ImCheck Therapeutics for Up to EUR 1 Billion to Enhance Oncology Pipeline"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads